Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma

1

The study investigates CD3xCD20 bispecific antibodies in patients with aggressive B-cell lymphoma and CNS involvement.
2

Eighteen patients with active CNS involvement had a 56% overall response rate and a 65% CNS-specific response rate.
3

In patients with prior CNS involvement, the overall response rate was 60%, with a complete response rate of 50%.
4

The 6-month progression-free survival for patients with active CNS involvement was 43%, while it was 46% for those with prior involvement.
5

Cytokine release syndrome occurred in 12 patients, highlighting the need for monitoring during treatment.

Blood Cancer Journal

by Karan L. Chohan, Rina L. Welkie, James Godfrey, Steven Bair, Lorenzo Falchi, Manali Kamdar, Ajay Major, Wendy Dixon, Jennifer Crombie, Reid Merryman, Sonia Godbole, Gilles Salles, Omnia Farahat, Amy Ayers, Ayushi Chauhan, Alex Herrera, Geoffrey Shouse, Sairah Ahmed, Yazeed Sawalha
May 22, 2026

1